ALDR stock forecast
Our latest prediction for Alder Biopharmaceuticals, Inc.'s stock price was made on the Feb. 9, 2017 when the stock price was at 25.00$.
In the short term (2weeks), ALDR's stock price should underperform the market by 0.00%. During that period the price should oscillate between -8.96% and +14.68%.
In the medium term (3months), ALDR's stock price should outperform the market by 1.06%. During that period the price should oscillate between -20.27% and +39.00%.Get email alerts
About Alder Biopharmaceuticals, Inc.
Alder Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which discovers, develops and commercializes various therapeutic antibodies. Its product portfolio includes ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine; and Clazakizumab, Alder's third program, is a monoclonal antibody candidate that inhibits interleukin-6. The company was founded by Randall C. Schatzman, Mark J. Litton, and John A. Latham in January 2004 and is headquartered in Bothell, WA.
At the moment the company generates 1M USD in revenues.
On its last earning announcement, the company reported a loss of -4.38$ per share.
The book value per share is 3.51$
Three months stock forecastFeb. 9, 2017
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|